Rain Oncology Inc (NAS:RAIN)
$ 1.21 0 (0%) Market Cap: 44.02 Mil Enterprise Value: -32.85 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 22/100

Rain Oncology Inc to Discuss the Topline Data from Phase 3 MANTRA Trial Call Transcript

May 22, 2023 / 12:30PM GMT
Release Date Price: $1.22 (-87.71%)
Operator

Greetings, and welcome to the Rain Oncology Phase III Topline Results Data Call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Dan Ferry, Managing Director of LifeSci Advisors. Please go ahead, sir.

Daniel Ferry
LifeSci Advisors, LLC - MD & Relationship Manager

Thank you, operator. Good morning, and thank you for joining us on the conference call to discuss the topline results of Rain's Phase III MANTRA trial of milademetan in dedifferentiated liposarcoma. On the call with me today are Avanish Vellanki, Co-Founder, Chairman and Chief Executive Officer of Rain Oncology; Dr. Robert Doebele, Co-Founder and Chief Scientific Officer; Dr. Richard Bryce, Chief Medical Officer; and Nelson Cabatuan, SVP of Finance.

Earlier this morning, Rain issued a press release with topline data from the Phase III MANTRA study. This release is accessible in the News and Press Releases section of Rain's website at www

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot